Symbiotec Pharmalab Limited has made an initial public offering aggregating to ₹ 2,180 crore, comprising a fresh issue of ₹150 crore and an offer for sale of ₹2,030 crore by certain existing shareholders.

Khaitan & Co advised Symbiotec Pharmalab on this IPO.

The transaction team consisted of Gautham Srinivas (Partner), Sathvik Ponnappa (Partner), Pulkit Singh Rahangdale (Principal Associate), Associates Anubhav Jaiswal, Sarvesh Sharma, Dharini Shanker, Anushaka Sharma, Swadha Swaroop and Naman Seth.

TT&A advised JM Financial Limited, Avendus Capital Private Limited, Motilal Oswal Investment Advisors Limited and Nomura Financial Advisory and Securities (India) Private Limited, the book running lead managers on this IPO.

The transaction team consisted of Abhinav Kumar (Partner), Shubham Sancheti (Managing Associate), Associates Abhishek Iyer, Daniyal Khan, Akshita Sharma, Harsh Shekhar and Jahnavi Seethamraju.

Hogan Lovells served as the international legal counsel to the BRLMs on this IPO.

The transaction team was led by Biswajit Chatterjee (Head of India Practice and Dubai Office Managing Partner).

Symbiotec Pharmalab is a research and development-driven, science-based pharmaceutical and biotechnology company with capabilities across three platforms- organic chemistry, biotechnology and complex injectables. The company has a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients ("APIs") in volume and value terms in Fiscal 2025.

If you would like your Deals, Columns, Press Releases to be published on Bar & Bench, please fill in the form available here.